Abstract: Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Abstract: The present technology relates generally to oligolactic acid conjugates of paclitaxel, rapamycin, selumetinib, and other anticancer agents, micelle compositions containing such conjugates and methods of preparing and using such compositions to treat various cancers. Specifically, there are provided oligolactic acid conjugates wherein the oligolactic acid comprises 2 to 24 lactic acid subunits and is attached through an ester linkage to the oxygen of the 7-hydroxyl of the paclitaxel or paclitaxel derivative, the 40-hydroxyl of the rapamycin or rapamycin derivative, and the 2?-hydroxyl of the selumetinib or selumetinib derivative. Compositions comprising water and a micelle comprising a polylactic acid-containing polymer and the oligolactic acid conjugate may be readily prepared. Methods of inhibiting or killing cancer cells and treating paclitaxel, rapamycin, and/or selumetinib cancers are also provided.

Abstract: The present invention features a method of treating leptomeningeal carcinomatosis in a subject using a peptide-therapeutic conjugate as exemplified by the agent ANG1005.

Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.

Abstract: What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L1 and L2 are the same or different, each a linear alkylene or alkenylene consisting of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention is directed to methods for the treatment or prevention of oxidative stress in a cell, e.g., photoreceptor cell, and methods for the treatment and prevention of disorders associated therewith by the administration of an agent, e.g., a nucleic acid molecule, which increases the expression and/or activity of an antioxidant defense protein.

Abstract: The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of a GALGT2 polynucleotide. The disclosure provides rAAV and methods of using the rAAV for GALGT2 gene therapy of neuromuscular disorders. Exemplary neuromuscular disorders include, but are not limited to, muscular dystrophies such as Duchenne muscular dystrophy, Congenital Muscular Dystrophy 1A and Limb Girdle Muscular Dystrophy 2D.

Abstract: The present disclosure provides imaging agents that are useful for the detection and evaluation of heart conditions, such as myocardial infarction. Upon activation, the imaging agents of the present disclosure may be detected using an ultrasound imaging device.

Abstract: The present application provides a means for differential diagnosis of Parkinson's disease and the clinically similar Parkinsonian disorders multiple system atrophy with predominantly Parkinsonian features (MSA-P) and progressive supranuclear palsy (PSP).

Abstract: Methods for detecting or ruling out a meningioma in a patient using a phenylbenzothiazole derivative or a stilbene derivative or a biphenylalkyne derivative, and a medical imaging technique such as positron emission tomography/computed tomography are disclosed.

Abstract: The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.

Abstract: Disclosed are compositions comprising polymeric nanoparticles and methods of using the same. The polymeric nanoparticles can be conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein. The polymeric nanoparticles can also comprises an imaging compound and/or a therapeutic agent encapsulated in the hydrophobic interior of the nanoparticle. A cancer therapeutic composition comprising the nanoparticle is also disclosed. The disclosed nanoparticles can be used to target and deliver imaging and/or therapeutic compounds to cancer cells, thereby identifying and/or treating a solid tumor cell target. Methods for treating cancer, such as lung cancer, using the polymeric nanoparticles are also disclosed.

Abstract: Methods and Apparatus are provided for irradiating a liquid with accelerated electrons. The liquid is prepared. The liquid is mixed with particles having at least one luminescent substance, where the particles are formed such that the particles are dispersed in the liquid after mixing. The liquid is irradiated with an electromagnetic radiation, which induces the at least one luminescent substance to luminesce. An actual value of a physical quantity characterizing the luminescence of the luminescent substance is detected. The liquid is irradiated with accelerated electrons until the detected actual value corresponds to a target value.

Abstract: In an aeration method for an isolator system, an incubator is connected to an isolator through a chamber. After closing a door at each sidewall of the chamber, a decontaminating gas is supplied to the chamber through gas supply passages to decontaminate the inside thereof. Next, air is supplied into the chamber through the gas supply passages and an initial aeration is carried out by discharging the decontamination gas through a gas discharge passage. Then, after a door between the isolator and the chamber is opened, and blowers are stopped, gas at a positive pressure in the isolator is introduced into the chamber. The decontaminating gas in the chamber is rapidly discharged to an outside through the gas supply passages and the gas discharge passage, and aeration in the chamber is completed. The time required for aeration of the chamber can be drastically reduced as compared with conventional aeration processes.

Abstract: The present disclosure generally relates to an ozone sanitizing system and method. In one embodiment, a system for sanitizing various objects using ozone gas is disclosed. The system comprises an ozone generating device configured generate ozone gas for sanitizing one or more objects, and a vessel configured to couple with the ozone generating device for receiving the ozone gas to sanitize the one or more objects stored inside the vessel during an ozone sanitizing cycle. The system is configured to recirculate at least a gas mixture generated during the ozone sanitizing cycle to increase an ozone concentration inside the vessel.

Abstract: A germ-reducing pen container including a body having a hollow passageway extending therethrough from an insertion end to a distal end for receiving a pen, the hollow passageway having at least one ultraviolet C light operatively attached thereto, an indicator on an outer surface of the body, and a dispensing mechanism operatively attached at the insertion end for dispensing the pen. A method of reducing germs on a pen, by inserting a pen into a body of a germ-reducing pen container, applying ultraviolet C light to the pen, killing the germs on the pen, indicating that the pen has been cleaned, and dispensing the pen.

Abstract: The present disclosure provides advantageous tray and bracket assembly that is configured and adapted to promote modularity and withstand the harsh environment of central sterile processing processes. Modular bracket assembly may be removed and relocated on tray without additional fasteners or components. Tray and bracket assembly may further provide identification features to correctly associate cataloged reusable medical devices to identified trays.

Abstract: A pouch filled with a fragrance material has a proximal end of a strap joined thereto. A first fastener is appended on a rear face of the strap, at or near the proximal end. A second fastener is appended on the rear face of the strap at or near the distal end of the strap. Preferably, a third fastener is on or appended to a rear face of the pouch. The second fastener, such as a male snap fastener, is removably joinable to either the first fastener to form a loop in the strap or to the third fastener so that the rear face of the strap faces the rear face of the pouch. The pouch may be suspended from a mounting structure, such as a neck of a rear-view mirror of an automobile, by the strap in either configuration.

Abstract: An ion generating device (1) includes discharge electrodes (21?22) each having a plurality of electrically conductive members (25?26) which form respective tip surfaces (36?37). A longer dimension direction of the tip surfaces (36?37) is nonparallel to an air sending direction (A). This allows for efficient release of ions.

Abstract: Devices and methods for sterilizing an enclosed space using ozone are disclosed herein. Various embodiments of the devices and methods also provide for accelerated degradation of the ozone upon sterilization. In some embodiments, a disclosed sterilization unit includes a first housing defining an ozone generation cavity, an ozone generator disposed within the ozone generation cavity, a second housing defining an ozone degradation cavity, and an ozone degrader disposed within the ozone degradation cavity. The sterilization unit of various embodiments is configured to cycle air between the enclosed space and the ozone generation cavity during an ozone generation cycle to sterilize the enclosed space; similarly, the unit is further configured to cycle air between the enclosed space and the ozone degradation cavity during an ozone degradation cycle to return the air within the enclosed space to safe ozone levels.

Abstract: A flexible ion generator device that includes a dielectric layer having a first end, a second end, a first side, a second side, a top side, and a bottom side, at least one trace positioned on the dielectric layer and having a plurality of emitters engaged to the at least one trace. A plurality of lights disposed on the dielectric layer.

Abstract: Disclosed is an absorbent article with biocompostable properties, such as a baby diaper, adult incontinence product, or a feminine hygiene pad. Particularly, the present invention is directed to a biocompostable absorbent sanitary article with a high degree of biocompostability. The sanitary article comprises, in one embodiment, at least a top layer, a back layer, and absorbent core, wherein the absorbent core includes a superabsorbent polymer, and wherein at least the superabsorbent polymer is biocompostable.

Abstract: The present invention is directed to tissue sealant compositions comprising: a multi-arm reactive polyethylene glycol polymer having at least 3 electrophilic groups; albumin; a buffer; water; and entrained gas as bubbles; wherein concentration of albumin in a liquid component of the sealant is within range of 50-200 mg/ml; and wherein concentration of multi-arm PEG in said liquid component of the sealant is within range of 25-100 mg/mL.

Abstract: Provided is an antibacterial biological implant capable of exhibiting superior antibacterial activity stably over a long period of time. The antibacterial biological implant 1 includes a substrate 2 made of a metal material and an anodized coating 3 provided on the substrate 2, the anodized coating 3 including an iodine-rich layer 31 located close to an interface S between the anodized coating 3 and the substrate 2.

Abstract: A patellar implant including a base portion formed of a porous metallic material, a polymeric portion formed of a polymeric material and attached to the base portion, and a membrane embedded between the base portion and the polymeric portion to provide a barrier between the porous metallic material and the polymer material.

Abstract: The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

Abstract: A stent, the stent including a first coating composition disposed on at least a portion of the outer surface of the stent, the first coating composition having at least one bioadhesive and a second coating composition disposed over the first coating composition, the second coating composition having at least one biodegradable polymer, and methods of making and using the same.

Abstract: Embodiments of the disclosure include lubricious coatings. In an embodiment the disclosure includes a lubricious coating for a medical device including first and second coated layers. The first coated layer is between the second coated layer and the device surface and includes a vinyl pyrrolidone polymer and a photo reactive group. The second coated layer is in direct contact with the first coated layer and is a top coating that includes an acrylic acid polymer. The second coated layer can optionally include photoreactive groups. The coating was found to have a very low number of particulates (e.g., 10 ?m or greater) which is very desirable for in vivo use.

Abstract: Two-dimensional materials, particularly graphene-based materials, having a plurality of apertures thereon can be formed into enclosures for various substances and introduced to an environment, particularly a biological environment (in vivo or in vitro). One or more selected substances can be released into the environment, one or more selected substances from the environment can enter the enclosure, one or more selected substances from the environment can be prevented from entering the enclosure, one or more selected substances can be retained within the enclosure, or combinations thereof. The enclosure can for example allow a sense-response paradigm to be realized. The enclosure can for example provide immunoisolation for materials, such as living cells, retained therein.

Abstract: Systems and methods related to polymer foams are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to a body cavity and placed in contact with, for example, tissue, injured tissue, internal organs, etc. In some embodiments, the polymer foams can be formed within a body cavity (i.e., in situ foam formation). In addition, the foamed polymers may be capable of exerting a pressure on an internal surface of a body cavity and preventing or limiting movement of a bodily fluid (e.g., blood, etc.).

Abstract: A method for controlling generation of biologically desirable voids in a composition placed in proximity to bone or other tissue in a patient by selecting at least one water-soluble inorganic material having a desired particle size and solubility, and mixing the water-soluble inorganic material with at least one poorly-water-soluble or biodegradable matrix material. The matrix material, after it is mixed with the water-soluble inorganic material, is placed into the patient in proximity to tissue so that the water-soluble inorganic material dissolves at a predetermined rate to generate biologically desirable voids in the matrix material into which bone or other tissue can then grow.

Abstract: An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate formed from a first material and a second material. At least one of the first and second materials includes a hemostatic agent. Kits, systems and methods are disclosed.

Abstract: There are disclosed implantable medical devices and apparatus for treating implantable medical devices during production, so as to cause the implantable medical devices to have abluminal surfaces and luminal surfaces with different functional characteristics and in particular surface energies. The luminal surfaces of the medical device are preferably coated with carbon, so as to have a low surface energy, which reduces the risk of thrombi forming when implanted into a patient's vessels. The abluminal surfaces are treated so as to have a high surface energy, such that a therapeutic, preferably bioactive, material, such as a drug, can adhere to the abluminal surfaces and preferably without any need for a containment layer such as polymer or other matrix material. Once the therapeutic material has been delivered into the tissue wall, the stent can remain within the patient's vessel without leaving any delivery artefacts, as occurs with some prior art drug eluting medical devices.

Abstract: A reduced-pressure canister includes a canister body having a fluid reservoir, an inlet for receiving fluids from a patient, and an integral hydrophobic filter formed within a side or top portion of the canister body. The integral hydrophobic filter has a plurality of pores in the canister body that are covered by a hydrophobic coating. Other canisters, methods, and systems are also presented.

Abstract: A surgical procedure for performing liposculpture on the human body comprising defining a surgical site where the liposculpture is to be performed including substantially 360 about at least the torso portion of the body and/or the limbs. The surgical site is infiltrated with a predetermined quantity of solution and subsequently performing multi-layer emulsification of fat deposits about the surgical site utilizing an ultrasound technology, wherein the multi-layer emulsification includes at least a superficial layer emulsification of fat deposits and a deep layer emulsification of fat deposits. Subsequently, a multi-layer liposuction extraction of the emulsified fat deposits is performed, wherein the multi-layer liposuction extraction comprises a deep layer liposuction; a superficial layer liposuction and an intermediate layer liposuction.

Abstract: A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

Abstract: The catheter device comprises a motor at the proximal end of the catheter device and a drive shaft, extending from the proximal end section to the distal end section of the catheter device, for driving a rotating element located at the distal end of the catheter device. The catheter device also comprises a hose-like catheter body which encompasses the drive shaft and extends from the proximal end section to the distal end section. At the proximal end of the catheter device, the drive shaft is connected to a motor by a clutch. The clutch is a magnetic clutch with a proximal and a distal magnet unit. The proximal magnet unit is connected to the motor and the distal magnet unit to the drive shaft. The distal magnet unit is mounted fluid-tight in a clutch housing. The proximal end of the catheter body makes a fluid-tight connection with the clutch housing.

Abstract: A blood pump system is implantable in a patient for ventricular support. A pumping chamber has an inlet for receiving blood from a ventricle of the patient. An impeller is received in the pumping chamber. A motor is coupled to the impeller for driving rotation of the impeller. A motor controller is provided for tracking systolic and diastolic phases of a cardiac cycle of the patient and supplying a variable voltage signal to the motor in a variable speed mode to produce a variable impeller speed linked to the cardiac cycle. The impeller speed comprises a ramping up to an elevated speed during the diastolic phase in order to reduce a load on the ventricle at the beginning of the systolic phase.

Abstract: The hemodialysis system includes a closed loop dialysate flow path which includes a dialyzer and a reservoir for storing dialysate, and a closed loop blood flow path which passes through the dialyzer in the opposite direction as the dialysate flow path. In addition, the hemodialysis system includes pumps for pumping dialysate and blood through their respective flow paths, a flow sensor for measuring the flow rate of dialysate in the dialysate flow path, and a level sensor for measuring the level of dialysate in the dialysate reservoir. A processor is connected to the flow sensor, reservoir level sensor and pumps to provide a first closed loop control system including the processor, flow sensor and a first dialysate pump, and a second closed loop control system including the processor, level sensor and a second dialysate pump which enable the processor to initiate, monitor and maintain ultrafiltration.

Abstract: The invention relates to fluid flow paths and fluid connectors for use with detachable containers that can be seated in an infusate caddy for use in a dialysis machine. The detachable containers can contain infusates or other solutes or materials such as disinfectants or cleaners, and can be conveniently seated in the infusate caddy. The detachable containers can be removed from the infusate caddy for restocking, cleaning, or resupply, as needed. The infusate caddy can be positioned or seated in a receiving compartment of a dialysis machine, and can also be removed, as needed. The fluid path and fluid connectors of the present invention provide the required fluid fittings, valve arrangements, pumps, and paddle assemblies for using the infusate caddy.

Abstract: Methods and devices for providing dialysis treatment are provided. The device comprises a cartridge for providing regenerative dialysis, the cartridge comprising: a body having an inlet and an outlet and defining an interior, the interior including at least a layer comprising urease, a layer comprising zirconium oxide, a layer comprising zirconium phosphate, and a layer comprising carbon, wherein at least two of the layers are blended together to provide a gradient of the two materials.

Abstract: The present invention is directed towards methods for therapeutically targeting circulating tumor cells during hemodialysis.

Abstract: A method of collecting mononuclear cells, comprising separating whole blood into cellular components and platelets suspended in plasma, separating the platelets suspended in plasma into platelet concentrate and platelet-poor plasma, combining the cellular components with the platelet-poor plasma to form a first mixture, and separating the first mixture into mononuclear cells and at least one component.

Abstract: A method for collecting plasma includes determining the weight, height, and hematocrit of a donor, and calculating a donor plasma volume and a target plasma collection volume. The target plasma collection volume is based on the donor plasma volume and a target percentage of plasma. The method then withdraws blood from the donor through a line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate the volume of pure plasma collected within the plasma collection container, and continue processing/collecting until the calculated volume of pure plasma equals the target plasma collection volume.

Abstract: An enema device and a method for using the same are disclosed. The enema device includes a non-plastic container and a liquid delivery tube. The non-plastic container is made of glass, stainless steel, or ceramic. The non-plastic container includes a bottom wall and an annular sidewall extending upwardly from the peripheral of the bottom wall, wherein the bottom wall has a bottom planar surface. The liquid delivery tube is in fluid communication with a containing chamber of the non-plastic container. Therefore, harmful effects to the human body from plasticizer can be prevented.

Abstract: An attachable needle assembly (102) for use on a medication delivery pen (104), the needle assembly (102) comprising a housing (1 10) enclosing a hub (106) having a communication needle (108) configured to engage the medication delivery pen (104) and pierce a reservoir septum of the medication delivery pen (104), a communication septum (172, 176) of the needle assembly (102) defining a septum chamber (180, 182) that is in fluid communication with the communication needle (108), a plurality of needles (118) disposed in the communication septum (172, 176), a follower ring (130) that determines which needle (124) of the plurality of needles (118) is to be selected, and a snap ring (136) that exposes the selected needle (124) and moves the selected needle (124) in fluid communication with the septum chamber (180, 182), wherein when the housing (110) is in a first position, the plurality of needles (118) is not exposed, and when the housing (110) is in a second position, the selected needle (124) is in fluid commu

Abstract: A dosing unit for use in an ambulatory infusion system, the dosing unit including: a dosing cylinder and a piston arranged inside the dosing cylinder and in a sliding displaceable manner along a displacement axis. The piston is convertible from a storing configuration into an operational configuration, wherein a circumferential sealing member of the piston is mechanically relieved in the storing configuration and is in sealing and sliding engagement with a circumferential inner surface of the dosing cylinder in the operational configuration. The dosing unit includes a configuration switch member in operative mechanical coupling with the piston, the configuration switch member being movable relative to the piston from a storing position into an operational position, thereby switching the piston configuration from the storing configuration to the operational configuration.

Abstract: A device and method for creating a fluid path are disclosed. A patch pump may include a start button. A force may be applied on a button needle in a force direction, based on activating the start button. A first end of the button needle may puncture a fluid container by moving the button needle from a first button needle position to a second button needle position via the force in the force direction. A second end of the button needle may be positioned underneath a carrier septum contained in a carrier, via the applied force. The carrier may be released based on activating the start button and the second end of the button needle, based on releasing the carrier, may puncture the carrier septum. A fluid path may be provided form the fluid container to a patient's tissue based on puncturing the fluid container and the carrier septum.

Abstract: A device includes: a first member comprising a first-member-side power transmission part; and a second member comprising a second-member-side power transmission part configured to be attachable to and detachable from the first member, the second member being a part of a medicinal-liquid administering device. The first-member-side power transmission part and the second-member-side power transmission part are configured to be engaged with each other for administering a medicinal liquid into a living body. The second member is configured to open a housing covering the first-member-side power transmission part to engage the second-member-side power transmission part with the first-member-side power transmission part at a time of attaching the first member to the second member.